Optimizing renal replacement therapy in older adults: a framework for making individualized decisions  by Tamura, Manjula Kurella et al.
Optimizing renal replacement therapy in older adults:
a framework for making individualized decisions
Manjula Kurella Tamura1,2, Jane C. Tan1 and Ann M. O’Hare3,4
1Division of Nephrology, Stanford University School of Medicine, Palo Alto, California, USA; 2Geriatric Research and Education
Clinical Center, Palo Alto Veterans Affairs Health Care System, Palo Alto, California, USA; 3Department of Medicine, University of
Washington, Seattle, Washington, USA and 4Department of Medicine and HSR&D Center of Excellence, Puget Sound Veterans Affairs
Health Care System, Seattle, Washington, USA
It is often difficult to synthesize information about the risks
and benefits of recommended management strategies in
older patients with end-stage renal disease since they may
have more comorbidity and lower life expectancy than
patients described in clinical trials or practice guidelines.
In this review, we outline a framework for individualizing
end-stage renal disease management decisions in older
patients. The framework considers three factors: life
expectancy, the risks and benefits of competing treatment
strategies, and patient preferences. We illustrate the use
of this framework by applying it to three key end-stage
renal disease decisions in older patients with varying
life expectancy: choice of dialysis modality, choice of
vascular access for hemodialysis, and referral for kidney
transplantation. In several instances, this approach might
provide support for treatment decisions that directly
contradict available practice guidelines, illustrating
circumstances when strict application of guidelines may
be inappropriate for certain patients. By combining
quantitative estimates of benefits and harms with qualitative
assessments of patient preferences, clinicians may be
better able to tailor treatment recommendations to
individual older patients, thereby improving the overall
quality of end-stage renal disease care.
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There is substantial variation in the type and intensity of care
provided to older patients with end-stage renal disease
(ESRD),1 stemming from uncertainty about the benefits and
harms of ESRD treatment strategies in this growing popu-
lation. Many older patients starting dialysis have multiple
chronic conditions in addition to ESRD.2 As comorbidity
accumulates, average life expectancy, functional status, and
quality of life decline. However, there is considerable hetero-
geneity in both life expectancy and treatment preferences
among older patients. This heterogeneity makes it difficult
to synthesize information about the risks and benefits of
recommended interventions for individual patients.
Clinical practice guidelines for ESRD care have tradition-
ally taken an age-neutral approach, allowing clinicians
flexibility to adapt guidelines to individual patients, but
providing little guidance about how to do this. Quality
improvement initiatives in ESRD care advocate for quality
benchmarks, but often fail to identify patients who may not
benefit from the standard of care. Some have noted that
both guidelines and quality initiatives do not acknowledge
the trade-offs involved in managing patients with multiple
chronic conditions, or the value that patients place on
achieving these outcomes.3
For example, although it may be intuitive that older
patients on average derive less benefit than their younger
counterparts from interventions like kidney transplantation,
some older patients may derive substantial benefit, whereas
others will not benefit at all and may even be harmed. For
interventions such as hypertension treatment, older adults
have a higher absolute risk of cardiovascular events but also a
higher risk of adverse events from treatment. Reconciling
these competing factors to make treatment decisions is often
complex and the resulting uncertainty can lead to both
under- and overtreatment of older adults.
Clinicians must also prioritize these treatment decisions
(e.g., by prioritizing the kidney transplant evaluation, there
may be less time for home dialysis training). Integrating
treatment preferences with considerations of risks and
benefits is central to individualized decision-making because
it allows patients to prioritize the outcomes that matter to
them.
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We propose a conceptual framework to guide manage-
ment decisions for older patients with ESRD. Our framework
is adapted from a framework proposed for cancer screening
in the elderly that considers three factors: life expectancy, the
benefits and harms of competing treatment strategies, and
the patient’s preferences.4 We apply this framework to three
aspects of decision-making for older patients with (or
expected to develop) ESRD: selection of a dialysis modality,
choice of vascular access for hemodialysis (HD), and referral
for kidney transplantation. Using available data, we provide
quantitative estimates to compare treatment strategies in
older patients with different life expectancies. Although there
are several established methods for quantifying an interven-
tion’s benefits or risks,5 we use the number needed to treat
(NNT), the reciprocal of the absolute risk reduction. There is
no one value for the NNT that defines a beneficial inter-
vention; however the closer to 1 the NNT then the larger the
benefit. Details of the data sources and the computational
methods are provided in the Supplementary Information
online. Using this framework, we illustrate how clinicians
could more effectively tailor treatment strategies to indivi-
dual ESRD patients by combining quantitative estimates of
benefits and harms with qualitative assessments of patient
preferences.
LIFE EXPECTANCY AFTER DIALYSIS INITIATION AMONG
OLDER PATIENTS
Life expectancy after the start of dialysis for the 25th, 50th and
75th percentile of patients aged 65 and older in the United
States is presented in Figure 1. Median life expectancy declines
with age, from 2.5 years for 65–69 year olds, to 0.6 years for
patients X90 years. Among patients of similar ages, there is
considerable heterogeneity, including among the very elderly.
For example, life expectancy of an 80-year-old patient with
ESRD at the 75th percentile (3.0 years) is more similar to
the life expectancy of a 70-year-old patient also at the 75th
percentile (4.3 years) than it is to the life expectancy of an
80-year-old patient at the 25th percentile (0.4 years).
Clinical characteristics may help clinicians estimate a
patient’s life expectancy after dialysis initiation. For example,
Moss et al.6 described the utility of the surprise question
(‘Would I be surprised if this patient died in the next year?’)
for predicting short-term mortality. Validated prognostic
models may also be used to estimate life expectancy among
dialysis patients.7–10 Most focus on short-term mortality
risk,8,9 although some are also useful for predicting long-
term mortality risk.10 Several are simple enough to adapt to
practice.8,10 Perfectly accurate predictions of life expectancy
are not necessary to use this framework. Rather, reasonable
estimates of whether a patient is above or below the median
life expectancy for his or her age will allow clinicians to make
better assessments of the risks and benefits of various
management strategies.
DIALYSIS MODALITY SELECTION
Population-level risks and benefits of peritoneal dialysis
vs. hemodialysis
Among patients over the age of 65 with ESRD in the United
States, in-center HD is the initial modality for 93–98% of
patients, peritoneal dialysis (PD) is the initial modality for
2-5% of patients, preemptive kidney transplant for 0–2% of
patients, and home HD for o1% (Figure 2). Our discussion
of modality selection focuses on comparisons of in-center
HD vs. PD, as outcomes data for home HD, particularly in
the elderly, are limited. For the same reasons, we also
consider various PD modalities together.
Recent observational studies suggest that survival of inci-
dent PD patients in the US has improved over time, and
is now comparable to survival of incident HD patients.11,12
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Figure 1 |Quartiles of life expectancy after dialysis initiation
by age group.
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Figure 2 | Initial renal replacement therapy modality in the
United States in 2008, according to age group.
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A notable exception is the subgroup of diabetic patients
X65 years of age with comorbidity. In this subgroup
survival with PD has improved over time but remains
lower than for HD.11,12 Paradoxically the improvement in PD
survival for most patient subgroups has occurred as PD
utilization has declined, perhaps pointing to unmeasured
selection bias.
If survival is comparable or nearly comparable with PD
and HD, what other modality-related outcomes matter?
A variety of outcomes have been considered in the literature,
including modality transfer, peritonitis, sepsis, access proce-
dures, quality of life and satisfaction with care.13–15 Modality
transfer occurs more commonly with PD vs. HD, and is most
often attributable to medical causes—recurrent peritonitis,
ultrafiltration failure, and catheter malfunction.13 Modality
transfer is associated with greater treatment burden, higher
costs of care and possibly greater morbidity;16 thus it may be
an outcome that clinicians and patients would like to avoid.
Although in some countries older patients have similar or
lower rates of transfer from PD to HD as compared with
younger patients,14 in the US older patients are more likely to
transfer from PD to HD, and less likely to transfer from HD
to PD as compared with younger patients (Supplementary
Information online). In contrast to modality transfers,
serious infection related morbidity occurs more commonly
among HD patients, particularly those dialyzed through
central venous catheters (CVCs). Serious infection rates for
both modalities decline slightly between the ages of 65–85,
and then increase over the age of 85 for patients on HD.17
The competing effects of infectious morbidity and modality
transfer may explain the observation that early mortality is
lower for PD vs. HD, whereas late mortality is higher.18 That
is, PD confers an early benefit from avoiding infectious
morbidity associated with a CVC, but a higher late risk
due to the high rate of modality failure and transfer to HD
with a CVC.19
Risks and benefits of dialysis modalities in patients with
differing life expectancies
To assess the relative importance of these events in patients
with different life expectancies, we estimated the NNT with
PD vs. HD with a CVC to prevent one sepsis hospitalization.
We first calculated the remaining lifetime risk of sepsis
hospitalization for each modality. We then estimated the
absolute risk reduction associated with PD, allowing us to
calculate the NNT. Next, we compared this to the NNT
after incorporating the age-specific modality transfer rates
(Supplementary Information online), assuming that patients
who switch from PD to HD do so with a CVC.
This analysis shows that PD confers a substantial
advantage in reducing rates of hospitalization for sepsis as
compared with HD with a CVC among many older patients
(Table 1). For example, the NNT with PD to prevent one
sepsis hospitalization is six or less for older adults above the
75th percentile of life expectancy for their age group. In other
words, we would have to treat six older patients with these
characteristics with PD to prevent one sepsis hospitalization
due to HD with a CVC. The advantage of PD over HD with
a CVC diminishes after accounting for modality transfer.
For example, among patients aged 80–84 years with an
average life expectancy, the NNT increases from 11 to 17 after
accounting for modality transfer. For those in the lowest
quartile of life expectancy, the NNTs increase above 25.
This suggests that PD would confer a lower lifetime risk
of hospitalization for sepsis compared with HD with a CVC
in older adults with average or above average life expec-
tancy. However, in older adults with poor life expectancy
on dialysis, there is not a strong rationale for choosing
PD over HD with a CVC in order to reduce sepsis risk.
Similarly, in older patients with above average life expectancy
on dialysis, risk of sepsis does not provide a strong rationale
for choosing PD over HD with an arteriovenous fistula
(AVF) or graft (AVG) (NNTs425 for all age groups favoring
AVF or AVG over PD). If the rate of CVC-related sepsis is
significantly higher at some centers compared with national
averages, or if a substantial percentage of patients who
transfer from PD to HD are able to avoid CVCs, then
PD would be more favorable than the estimates presented
in Table 1.
With respect to patient-reported outcomes, changes in
quality of life over time are similar among PD vs. HD
patients, although PD patients report greater satisfaction
with care.15,20 PD patients require fewer access procedures
than patients receiving HD with a CVC.21 PD also preserves
residual renal function to a greater extent than HD.
This may allow older patients to maintain an attenuated
PD regimen with relatively low treatment burden for an
extended period of time. Conversely, because of higher
protein losses, PD may contribute to a higher incidence of
malnutrition.
Table 1 | Number needed to treat with PD to prevent one hospitalization for sepsis due to hemodialysis with a CVC
65–69 years 70–74 years 75–79 years 80–84 years 85–89 years X90 years
Quartiles of life expectancy
Treatment strategy 75th 50th 25th 75th 50th 25th 75th 50th 25th 75th 50th 25th 75th 50th 25th 75th 50th 25th
PD vs. CVC Model 1 3 6 17 3 5 17 3 7 22 5 11 37 4 11 39 6 16 51
PD vs. CVC Model 2 5 9 25 4 8 24 4 10 33 7 17 58 7 18 62 11 31 99
Abbreviations: CVC, central venous catheters; HD, hemodialysis; PD, peritoneal dialysis.
Model 1: Assumes patients remain on modality for their remaining lifetime.
Model 2: Incorporates age-specific modality switch rates (Supplementary Information online) and assumes that patients who switch from PD to HD do so with a CVC.
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VASCULAR ACCESS
Population-level risks and benefits of vascular access options
for hemodialysis
Guidelines recommend the use of a permanent access (vs.
CVC) for chronic dialysis, and strongly favor AVFs over
AVGs.22 These recommendations are based on the lower risk
of infection and thrombosis associated with AVF vs. AVG use,
and the high risk of infection associated with CVC use.
Higher rates of hospitalization and mortality have also been
reported for patients with AVGs compared with AVFs, and
CVCs compared with AVGs, although it is unclear to what
extent these results reflect confounding by unmeasured
differences between patients with these different forms of
access.22 Compared with AVGs, AVFs have higher patency
rates and require fewer procedures to maintain patency.22
However, they have the disadvantage of requiring a
substantial amount of time to mature and require more
procedures to achieve patency compared with AVGs. Many
AVFs ultimately fail to mature and time to maturation can be
extraordinarily difficult to predict in an individual patient.22
Older patients are generally more likely than their younger
counterparts to experience failed maturation.23,24 Although
AVGs require more secondary procedures than AVFs to
maintain patency, they can usually be used with reasonable
certainty within weeks of creation. CVCs have the unique
advantage that they can be placed at very short notice and
can be used immediately after placement. As the time
between access placement and first use is typically much
longer for AVFs than for AVGs, the decision to place
an AVF in preference to an AVG in a patient already receiving
dialysis usually implies longer time spent with a CVC.
In the US, approximately 80% of patients initiate chronic
HD with a CVC, either because a permanent access had
not been placed or because permanent access is not ready
for use.25
The relative advantages and disadvantages of these
different forms of access have been well documented on a
population level. However, because the benefits and harms
associated with each form of access accrue at different rates
over time,26,27 the net benefit of different access strategies
might vary between individuals as a function of life
expectancy. Although a variety of different outcomes
including patency, infection, mortality, and hospitalization
are more favorable for patients with an AVF compared with
other forms of access, these benefits do not accrue
immediately. For example, it is estimated that AVG survival
is actually superior to that of AVFs for the first 18 months
after creation, suggesting that patients with a life expectancy
of less than this do not experience the benefit of longer
patency expected after AVF placement.28 Patients whose life
expectancy is less than the 3–6 months required for
maturation cannot benefit from AVF placement. For patients
in whom maturation is expected to take longer than average
or those at high risk of maturation failure, a life expectancy
longer than six months would be needed to justify AVF
placement. Given the higher risk of bacteremia and other
adverse outcomes associated with CVC vs. AVG use, the need
for prolonged CVC use during AVF maturation may be
considered a harm if the patient will not live long enough to
reap the benefits of AVF vs. AVG placement.
The relative advantages and disadvantages of each form of
access may also vary depending on the timing of access
placement relative to dialysis initiation. Although most
patients undergo permanent access placement only after
dialysis initiation, guidelines recommend that permanent
access be placed in advance of the need for dialysis.22
Compared with access decisions for patients already on
dialysis, pre-dialysis access decisions involve an expanded and
more complex set of considerations. Not only is the time
required for AVF maturation unpredictable in individual
patients, the time available before dialysis initiation is usually
not known. There may also be uncertainty about whether the
patient will survive long enough to require dialysis.29,30
Patients may be uncertain about whether they would want
dialysis, should the need arise.31 Patients who do not survive
to the point of needing dialysis, or decide not to undergo
dialysis cannot benefit from access placement.30 One recent
study found that two-thirds of elderly decedents who had
undergone AVF placement died before their AVF was ever
used for dialysis, either because they did not start dialysis or
because their AVF did not reach maturity.32
Risks and benefits of vascular access strategies in patients
with differing life expectancies
To better understand the complex interplay between life
expectancy and the relative advantages and disadvantages of
these three distinct, but interdependent forms of HD
access, we estimated the remaining lifetime absolute risk
reduction in vascular access–related bacteremia attributable
to the use of a preferred vs. non-preferred form of access
(i.e., AVF vs. AVG and AVG vs. CVC, respectively) for patients
with differing life expectancy. We defined an access-related
bloodstream infection as a patient with a microorganism
identified in a blood culture where the source of infection was
the vascular access site.33 We used this information to
estimate the number of AVFs needed to prevent one episode
of AVG-related bacteremia and the number of AVGs needed
to prevent one episode of CVC-related bacteremia, respec-
tively. We first assumed that permanent access was functional
at the time of dialysis initiation. We then assumed that
permanent access was placed at the time of dialysis initiation
and that patients dialyzed with a CVC until their permanent
access was ready to use (we assumed that an AVF could be
used after three months and an AVG could be used after 0.5
months). As rates of bacteremia associated with CVCs may
vary considerably depending on local practices, these figures
may underestimate the benefits of AVFs over AVGs and
overestimate those of AVGs over CVCs at some centers.34,35
The same approach could be used to compare treat-
ment strategies for prevention of sepsis, a less common but
more severe complication, as we did above for modality
selection, or for prevention of vascular access infections
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not associated with bacteremia, a more common but less
severe complication.
Table 2 demonstrates that for older adults with more
limited life expectancy, AVFs confer a very modest reduction
in risk of bacteremia compared with AVGs when measured
from the time of first use. For example, among patients in the
oldest age group with a life expectancy in the 25th percentile,
more than 200 AVFs would be needed to prevent one episode
of AVG-related bacteremia. For patients with longer life
expectancy, the benefits of AVFs vs. AVGs in reducing the risk
of bacteremia are more tangible. For example, nine AVFs
would be needed to prevent one episode of AVG-related
bacteremia in patients aged 65–69 with a life expectancy in
the 75th percentile. AVF placement is associated with a
relatively greater reduction in risk of bacteremia among
patients in the oldest age group with a life expectancy in the
75th percentile than for patients in the youngest age group
with a life expectancy in the 25th percentile. Strikingly, any
advantages of AVF over AVG placement disappear for most
groups when we factor in a relatively modest lag between the
access creation and first use. Assuming that an AVF can be
used after 3 months and an AVG after 2 weeks, only patients
aged 65–80 with a life expectancy in the 75th percentile for
their age group would be expected to derive a benefit from
AVF vs. AVG placement. These findings suggest that AVFs do
not result in a lower lifetime risk of bacteremia compared
with AVGs in most older patients without a permanent access
at onset of ESRD, and that only those with longer life
expectancy will benefit from pre-emptive AVF placement.
As rates of bacteremia are an order of magnitude greater
for CVCs compared with AVGs, much less time is required
before the risk of bacteremia associated with a CVC exceeds
that associated with an AVG. For example, among patients
aged 65–69 with a life expectancy in the 75th percentile, less
than one AVG would be required to prevent one episode of
CVC-related bacteremia. Even among patients in this age
group with a life expectancy in the 25th percentile, only four
AVGs would be required to prevent one episode of CVC-
related bacteremia. Similar to the benefits of AVFs vs. AVGs,
the relative benefits of AVGs vs. CVCs decline with age and
life expectancy. Due to the shorter lag between access creation
and first use for AVGs compared with AVFs, the benefits of
AVG vs. CVC use would be predicted to be much less
sensitive to timing of AVG placement, although this could
vary depending on the timing of AVG placement. One recent
study in which AVGs were placed a median of 48 days after
dialysis initiation found an increased risk of catheter-related
bacteremia compared with pre-dialysis AVG placement.36
KIDNEY TRANSPLANTATION
Population-level risks and benefits of kidney transplantation
Decisions to pursue kidney transplantation involve consid-
erations of the risks and benefits of transplantation, and of
the transplantation referral and evaluation process. Thus,
clinicians need to consider not simply whether transplanta-
tion is likely to be beneficial in older adults, but whether a
strategy of transplant referral and evaluation is likely to be
beneficial. No specific age has been formally defined as an
upper limit for transplant candidacy, but rather, guidelines
suggest basing candidacy on ‘biologic rather than chrono-
logic age’.37 The criteria for accepting an older adult to the
waiting list are highly variable across centers and regions, and
this variation may affect the overall assessment of benefit
from pursuing transplantation. Living donor transplantation
is associated with improved survival compared with deceased
donor transplantation in all age groups examined.38 As
patterns of referral, acceptance, and timing of transplantation
differ according to whether a living donor is available, here
we focus on the risks and benefits of deceased donor kidney
transplantation.
The population-level benefits of deceased donor kidney
transplantation over chronic dialysis have been well estab-
lished. Long-term mortality is 48 to 82% lower among
deceased-donor transplant recipients than for patients on the
waiting list, translating into a doubling of life expectancy for
the average transplant recipient.39 Older adults can also
benefit from kidney transplantation. For example, compared
with patients who remain on the waiting list, transplantation
extends life by 4, 3, and 1 additional year for patients
aged 60–64, 65–69, and 70–74, respectively.39 A more recent
Table 2 | Number needed to treat with preferred access type to prevent one episode of vascular access–related bacteremia due
to non-preferred access
65–69 years 70–74 years 75–79 years 80–84 years 85–89 years X90 years
Treatment strategy to
Quartiles of life expectancy
prevent bacteremia 75th 50th 25th 75th 50th 25th 75th 50th 25th 75th 50th 25th 75th 50th 25th 75th 50th 25th
AVF vs. AVG Model 1 9 17 48 10 20 62 11 25 82 14 33 110 18 47 167 24 67 219
AVF vs. AVG Model 2 27 — — 35 — — 62 — — — — — — — — — — —
AVG vs. CVC Model 1 o1 1 4 o1 1 5 o1 2 6 1 2 8 1 4 12 2 5 16
AVG vs. CVC Model 3 o1 1 4 o1 2 5 o1 2 7 1 3 9 1 4 15 2 5 21
Abbreviations: AVF, arteriovenous fistula; AVG, arteriovenous graft; CVC, central venous catheter.
‘—’ indicates life expectancy is shorter than time required to achieve benefit from intervention.
Model 1: Assumes both access types are functional at the start of dialysis.
Model 2: Assumes patients with AVF dialyze via CVC for 3 months while AVF matures and that patients with an AVG dialyze for 0.5 months with a CVC until the AVG is ready
for use.
Model 3: Assumes patients with AVG dialyze via CVC for 0.5 months until the AVG is ready for use.
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analysis demonstrates that the benefits of transplantation
extend to wait-listed patients over the age of 75, and to
patients over the age of 70 with diabetes.40 Jassal and
colleagues found that kidney transplantation was cost-
effective for patients over the age of 65, but that the
attractiveness of transplantation declined as waiting time
increased.41 Short-term allograft survival is slightly lower for
older vs. younger adults but still excellent.40 These benefits
should be interpreted in the light of the strong selection bias
against older adults during the transplant referral, evaluation
and wait-listing process.42–44
The benefits of kidney transplantation do not accrue
immediately. Rather, transplant recipients incur an upfront
risk of mortality for the potential of a long-term benefit.
On average, the risk of death during the first 2 weeks after
transplantation is almost three-fold higher than that for
patients who remain on dialysis.39 This risk declines over
time and by eight months postoperatively, the cumulative
mortality from transplantation drops below that of wait-
listed patients who remain on dialysis.39 The length of time it
takes for transplantation to yield a survival benefit is longer
for older patients, reflecting higher postoperative mortality
rates (Figure 3).39,40
Beyond postoperative mortality, other potential harms
arising from transplantation and the evaluation process
should be considered. Although kidney transplantation
reduces long-term mortality on average, it increases the risk
for certain morbidities, including diabetes, some malignan-
cies and bone fractures. Several types of harm may also arise
from the transplant evaluation. First, complications may
occur as a result of diagnostic tests or procedures that are
part of the transplant evaluation. Second, the evaluation may
lead to unnecessary treatment of some conditions (e.g.,
treatment of low-grade prostate cancer). Third, false-positive
test results as a consequence of screening may lead to
psychological distress. Fourth, the transplant evaluation
process may take time away from other health priorities.
The advantages of transplantation cannot be realized until
patients are placed on the waiting list. For patients over 65
who are ultimately placed on the waiting list, the time from
dialysis initiation to wait-listing averages 7-8 months in the
US (Supplementary Information online). The longer the
evaluation process or the waiting time following dialysis
initiation, the higher the rate of death or inactivation due to
the development of serious comorbidity. This lowers the net
likelihood of benefit from pursuing kidney transplantation.
Risks and benefits of kidney transplantation in patients with
different life expectancies
We considered the benefits of deceased donor transplantation
vs. remaining on dialysis for patients of different life
expectancies. We assumed that patients were active on the
waiting list at the start of dialysis, and that transplantation
confers a benefit over remaining on the waiting list after
1.0–1.8 years (Supplementary Information online). Table 3
demonstrates that for older patients with a life expectancy
below the 25th percentile, deceased-donor transplantation
offers no additional benefit compared with remaining on
dialysis. However, the benefits of transplantation are fairly
robust for older patients with a life expectancy above the 75th
percentile. For example, four transplants would be needed to
prevent one death on the waiting list for patients aged 65–69
with a life expectancy above the 75th percentile. As would be
anticipated, the benefit of transplantation declines with age.
Still, for patients up to 84 years of age in the highest quartile
of life expectancy, the NNT to prevent one death on the
waiting list appears low enough to justify transplantation,
assuming patients are active on the waiting list at the start of
dialysis. When the lag time to wait-listing is factored in, the
benefits of transplantation are lower. This is most clearly
demonstrated for patients in the 70–74-year age group with a
life expectancy near the median, where the NNT increases
from 19 to 402 with the incorporation of a 7-month delay
from the start of dialysis to wait-listing. For patients aged
65–79 with a life expectancy above the 75th percentile,
transplantation remains favorable even after accounting for
a delay in wait-listing.
These estimates may be modified by patient or regional
factors. For example, if 10% of waiting time is spent in
inactive status,40 then the NNT remains below 10 only for
patients aged 65–74 with a life expectancy above the 75th
percentile. Very long waiting times may also affect the relative
advantages of an expanded criteria donor (ECD) vs. a
standard criteria donor (SCD). The ECD list shortens waiting
times compared with the SCD list, but at the expense of a
higher risk for allograft loss. Patients more vulnerable to
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Figure 3 | Time required for cumulative survival after kidney
transplantation to exceed cumulative survival on the waiting
list, by age group. Data are adapted from Wolfe et al.39 and Rao
et al.40
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poorer health or death while on the waitlist, and those in
regions with longer waiting times may benefit from an ECD
transplant.45 For example, in regions where the median
waiting time exceeds 4 years, the waiting time for an SCD
transplant would exceed the life expectancy of most patients
over the age of 65. In contrast, in regions where the median
waiting time is less than 2 years, the choice between ECD and
SCD transplantation must be based on the balance between
the additional time on the waiting list for an SCD transplant
vs. reduced allograft life of an ECD transplant.
Still, determining which older adults will benefit from
initiating a transplant evaluation and when to begin this
process can be challenging. Preemptive transplantation is
associated with the largest survival advantage, even in older
adults, and as illustrated in Table 3, a delay in placing
otherwise suitable patients on the waiting list could reduce
the benefits of pursuing transplantation. However, in some
cases it may be unclear whether an older patient is likely to
progress to ESRD. Initiating a transplant evaluation in these
patients would expose them to the potential harms of
unnecessary diagnostic testing with little possibility for
benefit. Among older patients already on dialysis, there
may be uncertainty about the outcome of the transplant
evaluation. Thus, there may also be reluctance to refer
patients for transplantation if the likelihood of successfully
completing the transplant workup is felt to be low. In one
study 27% of patients over age 55 and interested in trans-
plantation completed the transplant evaluation and were
placed on the waiting list.46 If applied to the data in Table 3,
then 15 patients aged 65–69 with a life expectancy above the
75th percentile and 63 patients with a life expectancy near the
median would need to be referred, respectively, in order to
prevent one death on dialysis. These data illustrate how non-
transparent wait-listing practices may make initiation of a
transplant evaluation an unattractive management strategy
among otherwise suitable candidates.
PATIENT PREFERENCES
The last step in this framework is the incorporation of patient
preferences. It allows for the possibility that different patients
may require very different benefit thresholds (i.e., NNTs) to
favor a given treatment strategy and may prioritize outcomes
differently. In other words, the outcomes that matter most to
clinicians and policy-makers may not be the ones that matter
most to patients. For example, the decision to place an
AVG over a CVC in an 85-year-old patient with poor life
expectancy may not be considered straightforward (NNT
15 to prevent one episode of CVC-related bacteremia). By
incorporating the patient’s preferences, such as a desire to
avoid cannulation pain and focus on short-term goals, the
appropriate course may become more apparent. In one study
30% of patients were willing to accept a substantially higher
mortality risk in order to remain on their current modality.20
Similar findings are suggested in qualitative studies of
vascular access preferences.47 The decision to pursue kidney
transplantation in a 65-year-old patient with above average
life expectancy may seem clear-cut (NNT 4-17). However,
for patients with concerns about the postoperative risks or a
desire to avoid the uncertainties of the evaluation process, it
may not be worth the potential benefits. For this framework
to be effective, it is imperative that information is commu-
nicated when patients are receptive, that misperceptions are
clarified, and that modifiable barriers to care are addressed.
Clinicians should also be mindful that preferences evolve over
time and may need to be revisited.48
COMMENT
We have outlined a framework for individualizing renal
replacement therapy decisions in older patients. The
advantage of this framework is that it provides a systematic
approach to consider risks, benefits and preferences for
competing treatment strategies based on life expectancy. In
doing so, it highlights how ESRD care might be optimized for
the subset of patients with the lowest life expectancy and
highest costs of care, a group often neglected in clinical trials
or practice guidelines. The specific quantitative estimates of
benefits and risks that we use to illustrate this approach are
limited by the availability of comparative-effectiveness data
and the lack of randomized controlled trials for many
management decisions in ESRD. Unmeasured selection biases
may have caused us to overestimate the benefits of certain
treatment strategies, although these same limitations also
apply to widely used practice guidelines. In addition,
uncertainty about whether and when older adults will initiate
Table 3 | Number needed to transplant to prevent one death on waiting list
65–69 years 70–74 years 75–79 years 80–84 years 85–89 years X90 years
Quartiles of life expectancy
Treatment strategy 75th 50th 25th 75th 50th 25th 75th 50th 25th 75th 50th 25th 75th 50th 25th 75th 50th 25th
Deceased donor txp
vs. waitlist Model 1
4 9 — 5 19 — 7 — — 11 — — 25 — — — — —
Deceased donor txp
vs. waitlist Model 2
4 17 — 6 402 — 10 — — 21 — — — — — — — —
Abbreviation: txp, transplant.
‘—’ indicates life expectancy is shorter than time required to achieve benefit from intervention.
Model 1: Assumes patients are active on waiting list at the start of dialysis.
Model 2: Incorporates age-specific lag from start of dialysis to transplant wait-listing (Supplementary Information online).
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chronic dialysis may impact decisions about preparatory
interventions such as pre-emptive access placement and
transplant. This framework can be updated as new informa-
tion becomes available and could be applied to other aspects
of ESRD care. In several instances, this approach might
provide support for treatment decisions that directly contra-
dict available practice guidelines, illustrating circumstances
when strict application of guidelines may be inappropriate
for certain patients. In summary, by identifying effective
treatments that align with patient priorities, this framework
may be able to improve the overall quality of ESRD care for
older patients.
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